An Open Trial of Iloperidone for Mixed Episodes in Bipolar Disorder

Vivek Singh, Jodi Gonzalez Arnold, Thomas J. Prihoda, Melissa Martinez, Charles L. Bowden

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background Mixed mood states in bipolar disorder are difficult to treat and when present indicate worse illness trajectories. Several medications are US Food and Drug Administration approved to treat mixed episodes; however, the clinical trials have been short term and rarely reported depression response. Methods We conducted a 5-month open-label trial examining the tolerability and efficacy of iloperidone for bipolar disorder mixed episodes. Results Mania and depression scores significantly improved over the course of the study for study completers (ie, 60%-68% improvement for manic symptoms and 41%-49% for depression symptoms). Improvements were observed early in the trial and after adjusting for concomitant medication effects. The average daily dose in completers was 15 mg. Thirty-nine percent (12/31) of the eligible sample discontinued early because of adverse effects. The adverse events most commonly associated with withdrawal were increased heart rate/palpitations (n = 5 of 12) and urinary incontinence/intense urge to urinate (n = 3 of 12). Conclusions In a subset of patients, iloperidone provides relief for classic manic, depression, and irritability symptoms associated with mixed episodes in a long-term trial. Adverse effect profiles are likely to be a major factor contributing to individualized medication use.

Original languageEnglish (US)
Pages (from-to)615-619
Number of pages5
JournalJournal of Clinical Psychopharmacology
Volume37
Issue number5
DOIs
StatePublished - Oct 1 2017

Fingerprint

Bipolar Disorder
Depression
Urge Urinary Incontinence
United States Food and Drug Administration
Heart Rate
Clinical Trials
iloperidone

Keywords

  • antipsychotic agents
  • bipolar disorder
  • iloperidone
  • mixed episode

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Pharmacology (medical)

Cite this

Singh, V., Arnold, J. G., Prihoda, T. J., Martinez, M., & Bowden, C. L. (2017). An Open Trial of Iloperidone for Mixed Episodes in Bipolar Disorder. Journal of Clinical Psychopharmacology, 37(5), 615-619. https://doi.org/10.1097/JCP.0000000000000764

An Open Trial of Iloperidone for Mixed Episodes in Bipolar Disorder. / Singh, Vivek; Arnold, Jodi Gonzalez; Prihoda, Thomas J.; Martinez, Melissa; Bowden, Charles L.

In: Journal of Clinical Psychopharmacology, Vol. 37, No. 5, 01.10.2017, p. 615-619.

Research output: Contribution to journalArticle

Singh, V, Arnold, JG, Prihoda, TJ, Martinez, M & Bowden, CL 2017, 'An Open Trial of Iloperidone for Mixed Episodes in Bipolar Disorder', Journal of Clinical Psychopharmacology, vol. 37, no. 5, pp. 615-619. https://doi.org/10.1097/JCP.0000000000000764
Singh, Vivek ; Arnold, Jodi Gonzalez ; Prihoda, Thomas J. ; Martinez, Melissa ; Bowden, Charles L. / An Open Trial of Iloperidone for Mixed Episodes in Bipolar Disorder. In: Journal of Clinical Psychopharmacology. 2017 ; Vol. 37, No. 5. pp. 615-619.
@article{1b61d1c5cb8946ff92e83be160656358,
title = "An Open Trial of Iloperidone for Mixed Episodes in Bipolar Disorder",
abstract = "Background Mixed mood states in bipolar disorder are difficult to treat and when present indicate worse illness trajectories. Several medications are US Food and Drug Administration approved to treat mixed episodes; however, the clinical trials have been short term and rarely reported depression response. Methods We conducted a 5-month open-label trial examining the tolerability and efficacy of iloperidone for bipolar disorder mixed episodes. Results Mania and depression scores significantly improved over the course of the study for study completers (ie, 60{\%}-68{\%} improvement for manic symptoms and 41{\%}-49{\%} for depression symptoms). Improvements were observed early in the trial and after adjusting for concomitant medication effects. The average daily dose in completers was 15 mg. Thirty-nine percent (12/31) of the eligible sample discontinued early because of adverse effects. The adverse events most commonly associated with withdrawal were increased heart rate/palpitations (n = 5 of 12) and urinary incontinence/intense urge to urinate (n = 3 of 12). Conclusions In a subset of patients, iloperidone provides relief for classic manic, depression, and irritability symptoms associated with mixed episodes in a long-term trial. Adverse effect profiles are likely to be a major factor contributing to individualized medication use.",
keywords = "antipsychotic agents, bipolar disorder, iloperidone, mixed episode",
author = "Vivek Singh and Arnold, {Jodi Gonzalez} and Prihoda, {Thomas J.} and Melissa Martinez and Bowden, {Charles L.}",
year = "2017",
month = "10",
day = "1",
doi = "10.1097/JCP.0000000000000764",
language = "English (US)",
volume = "37",
pages = "615--619",
journal = "Journal of Clinical Psychopharmacology",
issn = "0271-0749",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - An Open Trial of Iloperidone for Mixed Episodes in Bipolar Disorder

AU - Singh, Vivek

AU - Arnold, Jodi Gonzalez

AU - Prihoda, Thomas J.

AU - Martinez, Melissa

AU - Bowden, Charles L.

PY - 2017/10/1

Y1 - 2017/10/1

N2 - Background Mixed mood states in bipolar disorder are difficult to treat and when present indicate worse illness trajectories. Several medications are US Food and Drug Administration approved to treat mixed episodes; however, the clinical trials have been short term and rarely reported depression response. Methods We conducted a 5-month open-label trial examining the tolerability and efficacy of iloperidone for bipolar disorder mixed episodes. Results Mania and depression scores significantly improved over the course of the study for study completers (ie, 60%-68% improvement for manic symptoms and 41%-49% for depression symptoms). Improvements were observed early in the trial and after adjusting for concomitant medication effects. The average daily dose in completers was 15 mg. Thirty-nine percent (12/31) of the eligible sample discontinued early because of adverse effects. The adverse events most commonly associated with withdrawal were increased heart rate/palpitations (n = 5 of 12) and urinary incontinence/intense urge to urinate (n = 3 of 12). Conclusions In a subset of patients, iloperidone provides relief for classic manic, depression, and irritability symptoms associated with mixed episodes in a long-term trial. Adverse effect profiles are likely to be a major factor contributing to individualized medication use.

AB - Background Mixed mood states in bipolar disorder are difficult to treat and when present indicate worse illness trajectories. Several medications are US Food and Drug Administration approved to treat mixed episodes; however, the clinical trials have been short term and rarely reported depression response. Methods We conducted a 5-month open-label trial examining the tolerability and efficacy of iloperidone for bipolar disorder mixed episodes. Results Mania and depression scores significantly improved over the course of the study for study completers (ie, 60%-68% improvement for manic symptoms and 41%-49% for depression symptoms). Improvements were observed early in the trial and after adjusting for concomitant medication effects. The average daily dose in completers was 15 mg. Thirty-nine percent (12/31) of the eligible sample discontinued early because of adverse effects. The adverse events most commonly associated with withdrawal were increased heart rate/palpitations (n = 5 of 12) and urinary incontinence/intense urge to urinate (n = 3 of 12). Conclusions In a subset of patients, iloperidone provides relief for classic manic, depression, and irritability symptoms associated with mixed episodes in a long-term trial. Adverse effect profiles are likely to be a major factor contributing to individualized medication use.

KW - antipsychotic agents

KW - bipolar disorder

KW - iloperidone

KW - mixed episode

UR - http://www.scopus.com/inward/record.url?scp=85032445080&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85032445080&partnerID=8YFLogxK

U2 - 10.1097/JCP.0000000000000764

DO - 10.1097/JCP.0000000000000764

M3 - Article

VL - 37

SP - 615

EP - 619

JO - Journal of Clinical Psychopharmacology

JF - Journal of Clinical Psychopharmacology

SN - 0271-0749

IS - 5

ER -